Quest Diagnostics Incorporated (DGX.MX)
| Previous close | 2,458.05 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 0 |
| Market cap | 273.07B |
| Beta (5Y monthly) | 0.87 |
| PE ratio (TTM) | 20.49 |
| EPS (TTM) | 119.95 |
| Earnings date | 24 July 2024 - 29 July 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 05 Apr 2024 |
| 1y target est | N/A |
PR NewswireWorkforce Drug Test Cheating Surged in 2023, Finds Quest Diagnostics Drug Testing Index Analysis of Nearly 10 Million Drug Tests
The percentage of employees in the general U.S. workforce whose drug test showed signs of tampering increased by more than six-fold in 2023 versus the prior year, the highest rate ever in more than 30 years of annual reporting. This finding is part of a new analysis of nearly 9.8 million workforce drug tests released today by Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services. To view the full report, visit www.QuestDiagnostics.com/DTI.
- PR Newswire
Quest Diagnostics to Speak at the 2024 Leerink Partners Healthcare Crossroads Conference
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during a fireside chat at the 2024 Leerink Partners Healthcare Crossroads Conference in Austin, Texas on Wednesday, May 29, 2024, at 10:20 a.m. Eastern Time.
PR NewswireQuest Diagnostics Names Murali Balakumar Senior Vice President and Chief Information and Digital Officer
Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, announced today that Murali Balakumar, a veteran information technology healthcare business leader, has been named Senior Vice President and Chief Information and Digital Officer (CIDO).
